BioRestorative Therapies (BRTX) Operating Expenses (2010 - 2025)
BioRestorative Therapies' (BRTX) quarterly Operating Expenses came in at $3.8 million in Q4 2025, up 40.77% YoY from $2.7 million in Q4 2024, and up 3.59% on a QoQ basis from $3.7 million in Q3 2025.
BioRestorative Therapies (BRTX) Operating Expenses (2010 - 2025) Analysis & Trends
BioRestorative Therapies (BRTX) has 16 years of Operating Expenses data on file, last reported at $3.8 million in Q4 2025.
- Quarterly Operating Expenses rose 40.77% year-over-year to $3.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $16.0 million (up 33.99% YoY) and the FY2025 annual result came in at $16.0 million, up 33.99% from the prior year.
- Operating Expenses improved to $3.8 million in Q4 2025, from $3.7 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $15.1 million in Q1 2021 to a low of $2.5 million in Q3 2024.
- A 5-year average of $4.4 million and a median of $3.8 million in 2025 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2021 — Operating Expenses soared 1683.77% — and 2022, when it plunged 66.36%.
- Tracing BRTX's Operating Expenses over 5 years: stood at $4.0 million in 2021, then grew by 16.72% to $4.7 million in 2022, then sank by 30.85% to $3.2 million in 2023, then declined by 15.74% to $2.7 million in 2024, then soared by 40.77% to $3.8 million in 2025.
- The last three Operating Expenses figures came in at $3.8 million (Q4 2025), $3.7 million (Q3 2025), and $3.6 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | BioRestorative Therapies | 2.00 Mn | -953,752.60 | 17,964.00 | 3.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.84 Mn |
| Sep 30, 2025 | 3.71 Mn |
| Jun 30, 2025 | 3.60 Mn |
| Mar 31, 2025 | 4.83 Mn |
| Dec 31, 2024 | 2.73 Mn |
| Sep 30, 2024 | 2.50 Mn |
| Jun 30, 2024 | 2.55 Mn |
| Mar 31, 2024 | 4.14 Mn |
| Dec 31, 2023 | 3.24 Mn |
| Sep 30, 2023 | 3.14 Mn |
| Jun 30, 2023 | 3.18 Mn |
| Mar 31, 2023 | 5.81 Mn |
| Dec 31, 2022 | 4.69 Mn |
| Sep 30, 2022 | 4.64 Mn |
| Jun 30, 2022 | 4.70 Mn |
| Mar 31, 2022 | 5.07 Mn |
| Dec 31, 2021 | 4.01 Mn |
| Sep 30, 2021 | 3.70 Mn |
| Jun 30, 2021 | 3.57 Mn |
| Mar 31, 2021 | 15.07 Mn |